Body Vision Medical announces distribution agreements for Argentina, Bolivia, Paraguay, Uruguay and Mexico
Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced its exclusive distribution agreements with DeLeC Científica Uruguaya S.A. for Argentina, Bolivia, Paraguay and Uruguay and with Bio Scan S.A. for Mexico. These strategic partnerships facilitate Body Vision's aim to expand access to its cutting-edge LungVision™ real-time, intraoperative...
Absci, a generative AI drug creation company, and PrecisionLife®, a leading computational biology company driving precision medicine in complex chronic diseases, announced a collaboration to develop a joint portfolio of potential therapeutics addressing unmet medical needs. The collaboration combines Absci’s speed and strength in antibody design and optimization with...
ImmunoScape, a biotechnology company focused on the discovery and development of next-generation T cell receptor (TCR)-based therapeutics, and MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell targeting therapies, announced a collaboration agreement to discover...
Dxcover Limited, a clinical-stage diagnostics company pioneering Multi-Omic Spectral Analysis for early detection of multiple cancers, announced that Founder and newly announced CEO Matthew Baker, PhD, will be presenting at Biotech Showcase 2024. Prof. Baker will be presenting data from the company’s clinical studies in early detection of solid...
Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced that it has been included in a recent Gartner report, entitled, Emerging Tech: Tech Innovators for Generative AI NovelDrug Discovery.
About Standigm's technology
Standigm offers three complementary platforms for drug discovery and repurposing:
Standigm ASK, an AI-aided...
Owkin, a French-American biotechnology company that applies artificial intelligence (AI) to drug discovery, development, and diagnostics, announced that it has entered into a collaboration agreement with MSD, the trade name of Merck & Co Inc., Rahway NJ USA to develop and commercialize AI-powered digital pathology diagnostics for the EU...
Anagenex and Nimbus Therapeutics (Nimbus) announced they have initiated a research collaboration. Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI), will work closely with Nimbus to discover small molecule drugs for multiple challenging targets.
Through this multi-target collaboration, the companies will apply Anagenex’s...
Expanded Workflow Solutions and Targeted Consulting Services Help Enterprise Customers Quickly Maximize the Value of Technology Investments from Komodo and Beyond
Komodo Health announces the expansion of its enterprise engagement capabilities and launches a new, dedicated Enterprise Strategy and Transformation team. As data, technology, and AI continue to accelerate breakthrough...
Atomic AI’s ATOM-1 large language model (LLM) demonstrates state-of-the-art accuracy for predicting RNA structure and function
Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, announced that the Company has created the first large language model (LLM) leveraging chemical mapping data....
Life science data can be highly disjointed and complex yet rich in potential insights. There are a variety of common insight-generation activities carried out with functional groups and through different channels; however, the findings are often disjointed and rarely connected.
Consequently, insights are frequently missed in all the information noise....
